0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Anti-Parkinson Drugs Market Size, Status and Forecast 2021-2027
Published Date: July 2021
|
Report Code: QYRE-Auto-16F6021
Home | Market Reports | Business & Industrial | Pharmaceuticals & Biotech
Global Anti Parkinson Drugs Market Size Status and Forecast 2021 2027

Global Anti-Parkinson Drugs Market Size, Status and Forecast 2021-2027

Code: QYRE-Auto-16F6021
Report
July 2021
108 Pages
QYResearch
Region: Global,
Description
Table of Content
Tables & Figures
Anti-Parkinson Drugs are drugs used to treat Parkinson's disease.
The most commonly used Anti-Parkinson Drugs act on the dopaminergic system of the striatum and basal ganglia, or are central muscarinic antagonists.
Market Analysis and Insights: Global Anti-Parkinson Drugs Market
The global Anti-Parkinson Drugs market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Anti-Parkinson Drugs market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Anti-Parkinson Drugs market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Anti-Parkinson Drugs market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Anti-Parkinson Drugs market.
Global Anti-Parkinson Drugs Scope and Market Size
Anti-Parkinson Drugs market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Anti-Parkinson Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type

Dopaminergic
Dopamine Agonists
Enzyme Inhibitors
Others

Segment by Application

Hospital Pharmacy
Retail Pharmacy
Online Stores

BY REGION

North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

BY COMPANY

AbbVie
Mylan Laboratories
Valeant Pharmaceuticals
Novartis
GlaxoSmithKline
Zambon Pharmaceuticals
Pfizer, Inc.
Hoffmann-La Roche
Merck & Co.
Orion Pharma
UCB
Teva Pharmaceutical Industries Ltd.
Vertical Pharmaceuticals, LLC
ACADIA Pharmaceuticals Inc.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Anti-Parkinson Drugs Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Dopaminergic
1.2.3 Dopamine Agonists
1.2.4 Enzyme Inhibitors
1.2.5 Others
1.3 Market by Application
1.3.1 Global Anti-Parkinson Drugs Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Hospital Pharmacy
1.3.3 Retail Pharmacy
1.3.4 Online Stores
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Anti-Parkinson Drugs Market Perspective (2016-2027)
2.2 Anti-Parkinson Drugs Growth Trends by Regions
2.2.1 Anti-Parkinson Drugs Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Anti-Parkinson Drugs Historic Market Share by Regions (2016-2021)
2.2.3 Anti-Parkinson Drugs Forecasted Market Size by Regions (2022-2027)
2.3 Anti-Parkinson Drugs Industry Dynamic
2.3.1 Anti-Parkinson Drugs Market Trends
2.3.2 Anti-Parkinson Drugs Market Drivers
2.3.3 Anti-Parkinson Drugs Market Challenges
2.3.4 Anti-Parkinson Drugs Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Anti-Parkinson Drugs Players by Revenue
3.1.1 Global Top Anti-Parkinson Drugs Players by Revenue (2016-2021)
3.1.2 Global Anti-Parkinson Drugs Revenue Market Share by Players (2016-2021)
3.2 Global Anti-Parkinson Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Anti-Parkinson Drugs Revenue
3.4 Global Anti-Parkinson Drugs Market Concentration Ratio
3.4.1 Global Anti-Parkinson Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Anti-Parkinson Drugs Revenue in 2020
3.5 Anti-Parkinson Drugs Key Players Head office and Area Served
3.6 Key Players Anti-Parkinson Drugs Product Solution and Service
3.7 Date of Enter into Anti-Parkinson Drugs Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Anti-Parkinson Drugs Breakdown Data by Type
4.1 Global Anti-Parkinson Drugs Historic Market Size by Type (2016-2021)
4.2 Global Anti-Parkinson Drugs Forecasted Market Size by Type (2022-2027)
5 Anti-Parkinson Drugs Breakdown Data by Application
5.1 Global Anti-Parkinson Drugs Historic Market Size by Application (2016-2021)
5.2 Global Anti-Parkinson Drugs Forecasted Market Size by Application (2022-2027)
6 North America
6.1 North America Anti-Parkinson Drugs Market Size (2016-2027)
6.2 North America Anti-Parkinson Drugs Market Size by Type
6.2.1 North America Anti-Parkinson Drugs Market Size by Type (2016-2021)
6.2.2 North America Anti-Parkinson Drugs Market Size by Type (2022-2027)
6.2.3 North America Anti-Parkinson Drugs Market Size by Type (2016-2027)
6.3 North America Anti-Parkinson Drugs Market Size by Application
6.3.1 North America Anti-Parkinson Drugs Market Size by Application (2016-2021)
6.3.2 North America Anti-Parkinson Drugs Market Size by Application (2022-2027)
6.3.3 North America Anti-Parkinson Drugs Market Size by Application (2016-2027)
6.4 North America Anti-Parkinson Drugs Market Size by Country
6.4.1 North America Anti-Parkinson Drugs Market Size by Country (2016-2021)
6.4.2 North America Anti-Parkinson Drugs Market Size by Country (2022-2027)
6.4.3 United States
6.4.4 Canada
7 Europe
7.1 Europe Anti-Parkinson Drugs Market Size (2016-2027)
7.2 Europe Anti-Parkinson Drugs Market Size by Type
7.2.1 Europe Anti-Parkinson Drugs Market Size by Type (2016-2021)
7.2.2 Europe Anti-Parkinson Drugs Market Size by Type (2022-2027)
7.2.3 Europe Anti-Parkinson Drugs Market Size by Type (2016-2027)
7.3 Europe Anti-Parkinson Drugs Market Size by Application
7.3.1 Europe Anti-Parkinson Drugs Market Size by Application (2016-2021)
7.3.2 Europe Anti-Parkinson Drugs Market Size by Application (2022-2027)
7.3.3 Europe Anti-Parkinson Drugs Market Size by Application (2016-2027)
7.4 Europe Anti-Parkinson Drugs Market Size by Country
7.4.1 Europe Anti-Parkinson Drugs Market Size by Country (2016-2021)
7.4.2 Europe Anti-Parkinson Drugs Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic
8 Asia-Pacific
8.1 Asia-Pacific Anti-Parkinson Drugs Market Size (2016-2027)
8.2 Asia-Pacific Anti-Parkinson Drugs Market Size by Type
8.2.1 Asia-Pacific Anti-Parkinson Drugs Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Anti-Parkinson Drugs Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Anti-Parkinson Drugs Market Size by Type (2016-2027)
8.3 Asia-Pacific Anti-Parkinson Drugs Market Size by Application
8.3.1 Asia-Pacific Anti-Parkinson Drugs Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Anti-Parkinson Drugs Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Anti-Parkinson Drugs Market Size by Application (2016-2027)
8.4 Asia-Pacific Anti-Parkinson Drugs Market Size by Region
8.4.1 Asia-Pacific Anti-Parkinson Drugs Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Anti-Parkinson Drugs Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Anti-Parkinson Drugs Market Size (2016-2027)
9.2 Latin America Anti-Parkinson Drugs Market Size by Type
9.2.1 Latin America Anti-Parkinson Drugs Market Size by Type (2016-2021)
9.2.2 Latin America Anti-Parkinson Drugs Market Size by Type (2022-2027)
9.2.3 Latin America Anti-Parkinson Drugs Market Size by Type (2016-2027)
9.3 Latin America Anti-Parkinson Drugs Market Size by Application
9.3.1 Latin America Anti-Parkinson Drugs Market Size by Application (2016-2021)
9.3.2 Latin America Anti-Parkinson Drugs Market Size by Application (2022-2027)
9.3.3 Latin America Anti-Parkinson Drugs Market Size by Application (2016-2027)
9.4 Latin America Anti-Parkinson Drugs Market Size by Country
9.4.1 Latin America Anti-Parkinson Drugs Market Size by Country (2016-2021)
9.4.2 Latin America Anti-Parkinson Drugs Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Anti-Parkinson Drugs Market Size (2016-2027)
10.2 Middle East & Africa Anti-Parkinson Drugs Market Size by Type
10.2.1 Middle East & Africa Anti-Parkinson Drugs Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Anti-Parkinson Drugs Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Anti-Parkinson Drugs Market Size by Type (2016-2027)
10.3 Middle East & Africa Anti-Parkinson Drugs Market Size by Application
10.3.1 Middle East & Africa Anti-Parkinson Drugs Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Anti-Parkinson Drugs Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Anti-Parkinson Drugs Market Size by Application (2016-2027)
10.4 Middle East & Africa Anti-Parkinson Drugs Market Size by Country
10.4.1 Middle East & Africa Anti-Parkinson Drugs Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Anti-Parkinson Drugs Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 AbbVie
11.1.1 AbbVie Company Details
11.1.2 AbbVie Business Overview
11.1.3 AbbVie Anti-Parkinson Drugs Introduction
11.1.4 AbbVie Revenue in Anti-Parkinson Drugs Business (2016-2021)
11.1.5 AbbVie Recent Development
11.2 Mylan Laboratories
11.2.1 Mylan Laboratories Company Details
11.2.2 Mylan Laboratories Business Overview
11.2.3 Mylan Laboratories Anti-Parkinson Drugs Introduction
11.2.4 Mylan Laboratories Revenue in Anti-Parkinson Drugs Business (2016-2021)
11.2.5 Mylan Laboratories Recent Development
11.3 Valeant Pharmaceuticals
11.3.1 Valeant Pharmaceuticals Company Details
11.3.2 Valeant Pharmaceuticals Business Overview
11.3.3 Valeant Pharmaceuticals Anti-Parkinson Drugs Introduction
11.3.4 Valeant Pharmaceuticals Revenue in Anti-Parkinson Drugs Business (2016-2021)
11.3.5 Valeant Pharmaceuticals Recent Development
11.4 Novartis
11.4.1 Novartis Company Details
11.4.2 Novartis Business Overview
11.4.3 Novartis Anti-Parkinson Drugs Introduction
11.4.4 Novartis Revenue in Anti-Parkinson Drugs Business (2016-2021)
11.4.5 Novartis Recent Development
11.5 GlaxoSmithKline
11.5.1 GlaxoSmithKline Company Details
11.5.2 GlaxoSmithKline Business Overview
11.5.3 GlaxoSmithKline Anti-Parkinson Drugs Introduction
11.5.4 GlaxoSmithKline Revenue in Anti-Parkinson Drugs Business (2016-2021)
11.5.5 GlaxoSmithKline Recent Development
11.6 Zambon Pharmaceuticals
11.6.1 Zambon Pharmaceuticals Company Details
11.6.2 Zambon Pharmaceuticals Business Overview
11.6.3 Zambon Pharmaceuticals Anti-Parkinson Drugs Introduction
11.6.4 Zambon Pharmaceuticals Revenue in Anti-Parkinson Drugs Business (2016-2021)
11.6.5 Zambon Pharmaceuticals Recent Development
11.7 Pfizer, Inc.
11.7.1 Pfizer, Inc. Company Details
11.7.2 Pfizer, Inc. Business Overview
11.7.3 Pfizer, Inc. Anti-Parkinson Drugs Introduction
11.7.4 Pfizer, Inc. Revenue in Anti-Parkinson Drugs Business (2016-2021)
11.7.5 Pfizer, Inc. Recent Development
11.8 Hoffmann-La Roche
11.8.1 Hoffmann-La Roche Company Details
11.8.2 Hoffmann-La Roche Business Overview
11.8.3 Hoffmann-La Roche Anti-Parkinson Drugs Introduction
11.8.4 Hoffmann-La Roche Revenue in Anti-Parkinson Drugs Business (2016-2021)
11.8.5 Hoffmann-La Roche Recent Development
11.9 Merck & Co.
11.9.1 Merck & Co. Company Details
11.9.2 Merck & Co. Business Overview
11.9.3 Merck & Co. Anti-Parkinson Drugs Introduction
11.9.4 Merck & Co. Revenue in Anti-Parkinson Drugs Business (2016-2021)
11.9.5 Merck & Co. Recent Development
11.10 Orion Pharma
11.10.1 Orion Pharma Company Details
11.10.2 Orion Pharma Business Overview
11.10.3 Orion Pharma Anti-Parkinson Drugs Introduction
11.10.4 Orion Pharma Revenue in Anti-Parkinson Drugs Business (2016-2021)
11.10.5 Orion Pharma Recent Development
11.11 UCB
11.11.1 UCB Company Details
11.11.2 UCB Business Overview
11.11.3 UCB Anti-Parkinson Drugs Introduction
11.11.4 UCB Revenue in Anti-Parkinson Drugs Business (2016-2021)
11.11.5 UCB Recent Development
11.12 Teva Pharmaceutical Industries Ltd.
11.12.1 Teva Pharmaceutical Industries Ltd. Company Details
11.12.2 Teva Pharmaceutical Industries Ltd. Business Overview
11.12.3 Teva Pharmaceutical Industries Ltd. Anti-Parkinson Drugs Introduction
11.12.4 Teva Pharmaceutical Industries Ltd. Revenue in Anti-Parkinson Drugs Business (2016-2021)
11.12.5 Teva Pharmaceutical Industries Ltd. Recent Development
11.13 Vertical Pharmaceuticals, LLC
11.13.1 Vertical Pharmaceuticals, LLC Company Details
11.13.2 Vertical Pharmaceuticals, LLC Business Overview
11.13.3 Vertical Pharmaceuticals, LLC Anti-Parkinson Drugs Introduction
11.13.4 Vertical Pharmaceuticals, LLC Revenue in Anti-Parkinson Drugs Business (2016-2021)
11.13.5 Vertical Pharmaceuticals, LLC Recent Development
11.14 ACADIA Pharmaceuticals Inc.
11.14.1 ACADIA Pharmaceuticals Inc. Company Details
11.14.2 ACADIA Pharmaceuticals Inc. Business Overview
11.14.3 ACADIA Pharmaceuticals Inc. Anti-Parkinson Drugs Introduction
11.14.4 ACADIA Pharmaceuticals Inc. Revenue in Anti-Parkinson Drugs Business (2016-2021)
11.14.5 ACADIA Pharmaceuticals Inc. Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of Tables
    Table 1. Global Anti-Parkinson Drugs Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
    Table 2. Key Players of Dopaminergic
    Table 3. Key Players of Dopamine Agonists
    Table 4. Key Players of Enzyme Inhibitors
    Table 5. Key Players of Others
    Table 6. Global Anti-Parkinson Drugs Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
    Table 7. Global Anti-Parkinson Drugs Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
    Table 8. Global Anti-Parkinson Drugs Market Size by Regions (2016-2021) & (US$ Million)
    Table 9. Global Anti-Parkinson Drugs Market Share by Regions (2016-2021)
    Table 10. Global Anti-Parkinson Drugs Forecasted Market Size by Regions (2022-2027) & (US$ Million)
    Table 11. Global Anti-Parkinson Drugs Market Share by Regions (2022-2027)
    Table 12. Anti-Parkinson Drugs Market Trends
    Table 13. Anti-Parkinson Drugs Market Drivers
    Table 14. Anti-Parkinson Drugs Market Challenges
    Table 15. Anti-Parkinson Drugs Market Restraints
    Table 16. Global Anti-Parkinson Drugs Revenue by Players (2016-2021) & (US$ Million)
    Table 17. Global Anti-Parkinson Drugs Market Share by Players (2016-2021)
    Table 18. Global Top Anti-Parkinson Drugs Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Anti-Parkinson Drugs as of 2020)
    Table 19. Ranking of Global Top Anti-Parkinson Drugs Companies by Revenue (US$ Million) in 2020
    Table 20. Global 5 Largest Players Market Share by Anti-Parkinson Drugs Revenue (CR5 and HHI) & (2016-2021)
    Table 21. Key Players Headquarters and Area Served
    Table 22. Key Players Anti-Parkinson Drugs Product Solution and Service
    Table 23. Date of Enter into Anti-Parkinson Drugs Market
    Table 24. Mergers & Acquisitions, Expansion Plans
    Table 25. Global Anti-Parkinson Drugs Market Size by Type (2016-2021) (US$ Million)
    Table 26. Global Anti-Parkinson Drugs Revenue Market Share by Type (2016-2021)
    Table 27. Global Anti-Parkinson Drugs Forecasted Market Size by Type (2022-2027) (US$ Million)
    Table 28. Global Anti-Parkinson Drugs Revenue Market Share by Type (2022-2027) & (US$ Million)
    Table 29. Global Anti-Parkinson Drugs Market Size Share by Application (2016-2021) & (US$ Million)
    Table 30. Global Anti-Parkinson Drugs Revenue Market Share by Application (2016-2021)
    Table 31. Global Anti-Parkinson Drugs Forecasted Market Size by Application (2022-2027) (US$ Million)
    Table 32. Global Anti-Parkinson Drugs Revenue Market Share by Application (2022-2027) & (US$ Million)
    Table 33. North America Anti-Parkinson Drugs Market Size by Type (2016-2021) (US$ Million)
    Table 34. North America Anti-Parkinson Drugs Market Size by Type (2022-2027) & (US$ Million)
    Table 35. North America Anti-Parkinson Drugs Market Size by Application (2016-2021) (US$ Million)
    Table 36. North America Anti-Parkinson Drugs Market Size by Application (2022-2027) & (US$ Million)
    Table 37. North America Anti-Parkinson Drugs Market Size by Country (2016-2021) & (US$ Million)
    Table 38. North America Anti-Parkinson Drugs Market Size by Country (2022-2027) & (US$ Million)
    Table 39. Europe Anti-Parkinson Drugs Market Size by Type (2016-2021) (US$ Million)
    Table 40. Europe Anti-Parkinson Drugs Market Size by Type (2022-2027) & (US$ Million)
    Table 41. Europe Anti-Parkinson Drugs Market Size by Application (2016-2021) (US$ Million)
    Table 42. Europe Anti-Parkinson Drugs Market Size by Application (2022-2027) & (US$ Million)
    Table 43. Europe Anti-Parkinson Drugs Market Size by Country (2016-2021) & (US$ Million)
    Table 44. Europe Anti-Parkinson Drugs Market Size by Country (2022-2027) & (US$ Million)
    Table 45. Asia-Pacific Anti-Parkinson Drugs Market Size by Type (2016-2021) (US$ Million)
    Table 46. Asia-Pacific Anti-Parkinson Drugs Market Size by Type (2022-2027) & (US$ Million)
    Table 47. Asia-Pacific Anti-Parkinson Drugs Market Size by Application (2016-2021) (US$ Million)
    Table 48. Asia-Pacific Anti-Parkinson Drugs Market Size by Application (2022-2027) & (US$ Million)
    Table 49. Asia-Pacific Anti-Parkinson Drugs Market Size by Region (2016-2021) & (US$ Million)
    Table 50. Asia-Pacific Anti-Parkinson Drugs Market Size by Region (2022-2027) & (US$ Million)
    Table 51. Latin America Anti-Parkinson Drugs Market Size by Type (2016-2021) (US$ Million)
    Table 52. Latin America Anti-Parkinson Drugs Market Size by Type (2022-2027) & (US$ Million)
    Table 53. Latin America Anti-Parkinson Drugs Market Size by Application (2016-2021) (US$ Million)
    Table 54. Latin America Anti-Parkinson Drugs Market Size by Application (2022-2027) & (US$ Million)
    Table 55. Latin America Anti-Parkinson Drugs Market Size by Country (2016-2021) & (US$ Million)
    Table 56. Latin America Anti-Parkinson Drugs Market Size by Country (2022-2027) & (US$ Million)
    Table 57. Middle East & Africa Anti-Parkinson Drugs Market Size by Type (2016-2021) (US$ Million)
    Table 58. Middle East & Africa Anti-Parkinson Drugs Market Size by Type (2022-2027) & (US$ Million)
    Table 59. Middle East & Africa Anti-Parkinson Drugs Market Size by Application (2016-2021) (US$ Million)
    Table 60. Middle East & Africa Anti-Parkinson Drugs Market Size by Application (2022-2027) & (US$ Million)
    Table 61. Middle East & Africa Anti-Parkinson Drugs Market Size by Country (2016-2021) & (US$ Million)
    Table 62. Middle East & Africa Anti-Parkinson Drugs Market Size by Country (2022-2027) & (US$ Million)
    Table 63. AbbVie Company Details
    Table 64. AbbVie Business Overview
    Table 65. AbbVie Anti-Parkinson Drugs Product
    Table 66. AbbVie Revenue in Anti-Parkinson Drugs Business (2016-2021) & (US$ Million)
    Table 67. AbbVie Recent Development
    Table 68. Mylan Laboratories Company Details
    Table 69. Mylan Laboratories Business Overview
    Table 70. Mylan Laboratories Anti-Parkinson Drugs Product
    Table 71. Mylan Laboratories Revenue in Anti-Parkinson Drugs Business (2016-2021) & (US$ Million)
    Table 72. Mylan Laboratories Recent Development
    Table 73. Valeant Pharmaceuticals Company Details
    Table 74. Valeant Pharmaceuticals Business Overview
    Table 75. Valeant Pharmaceuticals Anti-Parkinson Drugs Product
    Table 76. Valeant Pharmaceuticals Revenue in Anti-Parkinson Drugs Business (2016-2021) & (US$ Million)
    Table 77. Valeant Pharmaceuticals Recent Development
    Table 78. Novartis Company Details
    Table 79. Novartis Business Overview
    Table 80. Novartis Anti-Parkinson Drugs Product
    Table 81. Novartis Revenue in Anti-Parkinson Drugs Business (2016-2021) & (US$ Million)
    Table 82. Novartis Recent Development
    Table 83. GlaxoSmithKline Company Details
    Table 84. GlaxoSmithKline Business Overview
    Table 85. GlaxoSmithKline Anti-Parkinson Drugs Product
    Table 86. GlaxoSmithKline Revenue in Anti-Parkinson Drugs Business (2016-2021) & (US$ Million)
    Table 87. GlaxoSmithKline Recent Development
    Table 88. Zambon Pharmaceuticals Company Details
    Table 89. Zambon Pharmaceuticals Business Overview
    Table 90. Zambon Pharmaceuticals Anti-Parkinson Drugs Product
    Table 91. Zambon Pharmaceuticals Revenue in Anti-Parkinson Drugs Business (2016-2021) & (US$ Million)
    Table 92. Zambon Pharmaceuticals Recent Development
    Table 93. Pfizer, Inc. Company Details
    Table 94. Pfizer, Inc. Business Overview
    Table 95. Pfizer, Inc. Anti-Parkinson Drugs Product
    Table 96. Pfizer, Inc. Revenue in Anti-Parkinson Drugs Business (2016-2021) & (US$ Million)
    Table 97. Pfizer, Inc. Recent Development
    Table 98. Hoffmann-La Roche Company Details
    Table 99. Hoffmann-La Roche Business Overview
    Table 100. Hoffmann-La Roche Revenue in Anti-Parkinson Drugs Business (2016-2021) & (US$ Million)
    Table 101. Hoffmann-La Roche Recent Development
    Table 102. Merck & Co. Company Details
    Table 103. Merck & Co. Business Overview
    Table 104. Merck & Co. Anti-Parkinson Drugs Product
    Table 105. Merck & Co. Revenue in Anti-Parkinson Drugs Business (2016-2021) & (US$ Million)
    Table 106. Merck & Co. Recent Development
    Table 107. Orion Pharma Company Details
    Table 108. Orion Pharma Business Overview
    Table 109. Orion Pharma Anti-Parkinson Drugs Product
    Table 110. Orion Pharma Revenue in Anti-Parkinson Drugs Business (2016-2021) & (US$ Million)
    Table 111. Orion Pharma Recent Development
    Table 112. UCB Company Details
    Table 113. UCB Business Overview
    Table 114. UCB Anti-Parkinson Drugs Product
    Table 115. UCB Revenue in Anti-Parkinson Drugs Business (2016-2021) & (US$ Million)
    Table 116. UCB Recent Development
    Table 117. Teva Pharmaceutical Industries Ltd. Company Details
    Table 118. Teva Pharmaceutical Industries Ltd. Business Overview
    Table 119. Teva Pharmaceutical Industries Ltd. Anti-Parkinson Drugs Product
    Table 120. Teva Pharmaceutical Industries Ltd. Revenue in Anti-Parkinson Drugs Business (2016-2021) & (US$ Million)
    Table 121. Teva Pharmaceutical Industries Ltd. Recent Development
    Table 122. Vertical Pharmaceuticals, LLC Company Details
    Table 123. Vertical Pharmaceuticals, LLC Business Overview
    Table 124. Vertical Pharmaceuticals, LLC Anti-Parkinson Drugs Product
    Table 125. Vertical Pharmaceuticals, LLC Revenue in Anti-Parkinson Drugs Business (2016-2021) & (US$ Million)
    Table 126. Vertical Pharmaceuticals, LLC Recent Development
    Table 127. ACADIA Pharmaceuticals Inc. Company Details
    Table 128. ACADIA Pharmaceuticals Inc. Business Overview
    Table 129. ACADIA Pharmaceuticals Inc. Anti-Parkinson Drugs Product
    Table 130. ACADIA Pharmaceuticals Inc. Revenue in Anti-Parkinson Drugs Business (2016-2021) & (US$ Million)
    Table 131. ACADIA Pharmaceuticals Inc. Recent Development
    Table 132. Research Programs/Design for This Report
    Table 133. Key Data Information from Secondary Sources
    Table 134. Key Data Information from Primary Sources
List of Figures
    Figure 1. Global Anti-Parkinson Drugs Market Share by Type: 2020 VS 2027
    Figure 2. Dopaminergic Features
    Figure 3. Dopamine Agonists Features
    Figure 4. Enzyme Inhibitors Features
    Figure 5. Others Features
    Figure 6. Global Anti-Parkinson Drugs Market Share by Application: 2020 VS 2027
    Figure 7. Hospital Pharmacy Case Studies
    Figure 8. Retail Pharmacy Case Studies
    Figure 9. Online Stores Case Studies
    Figure 10. Anti-Parkinson Drugs Report Years Considered
    Figure 11. Global Anti-Parkinson Drugs Market Size (US$ Million), Year-over-Year: 2016-2027
    Figure 12. Global Anti-Parkinson Drugs Market Size (US$ Million), 2016 VS 2021 VS 2027
    Figure 13. Global Anti-Parkinson Drugs Market Share by Regions: 2020 VS 2027
    Figure 14. Global Anti-Parkinson Drugs Market Share by Regions (2022-2027)
    Figure 15. Global Anti-Parkinson Drugs Market Share by Players in 2020
    Figure 16. Global Top Anti-Parkinson Drugs Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Anti-Parkinson Drugs as of 2020
    Figure 17. The Top 10 and 5 Players Market Share by Anti-Parkinson Drugs Revenue in 2020
    Figure 18. Global Anti-Parkinson Drugs Revenue Market Share by Type (2016-2021)
    Figure 19. Global Anti-Parkinson Drugs Revenue Market Share by Type (2022-2027)
    Figure 20. North America Anti-Parkinson Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 21. North America Anti-Parkinson Drugs Market Share by Type (2016-2027)
    Figure 22. North America Anti-Parkinson Drugs Market Share by Application (2016-2027)
    Figure 23. North America Anti-Parkinson Drugs Market Share by Country (2016-2027)
    Figure 24. United States Anti-Parkinson Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 25. Canada Anti-Parkinson Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 26. Europe Anti-Parkinson Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 27. Europe Anti-Parkinson Drugs Market Share by Type (2016-2027)
    Figure 28. Europe Anti-Parkinson Drugs Market Share by Application (2016-2027)
    Figure 29. Europe Anti-Parkinson Drugs Market Share by Country (2016-2027)
    Figure 30. Germany Anti-Parkinson Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 31. France Anti-Parkinson Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 32. U.K. Anti-Parkinson Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 33. Italy Anti-Parkinson Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 34. Russia Anti-Parkinson Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 35. Nordic Anti-Parkinson Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 36. Asia-Pacific Anti-Parkinson Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 37. Asia-Pacific Anti-Parkinson Drugs Market Share by Type (2016-2027)
    Figure 38. Asia-Pacific Anti-Parkinson Drugs Market Share by Application (2016-2027)
    Figure 39. Asia-Pacific Anti-Parkinson Drugs Market Share by Region (2016-2027)
    Figure 40. China Anti-Parkinson Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 41. Japan Anti-Parkinson Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 42. South Korea Anti-Parkinson Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 43. Southeast Asia Anti-Parkinson Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 44. India Anti-Parkinson Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 45. Australia Anti-Parkinson Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 46. Latin America Anti-Parkinson Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 47. Latin America Anti-Parkinson Drugs Market Share by Type (2016-2027)
    Figure 48. Latin America Anti-Parkinson Drugs Market Share by Application (2016-2027)
    Figure 49. Latin America Anti-Parkinson Drugs Market Share by Country (2016-2027)
    Figure 50. Mexico Anti-Parkinson Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 51. Brazil Anti-Parkinson Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 52. Middle East & Africa Anti-Parkinson Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 53. Middle East & Africa Anti-Parkinson Drugs Market Share by Type (2016-2027)
    Figure 54. Middle East & Africa Anti-Parkinson Drugs Market Share by Application (2016-2027)
    Figure 55. Middle East & Africa Anti-Parkinson Drugs Market Share by Country (2016-2027)
    Figure 56. Turkey Anti-Parkinson Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 57. Saudi Arabia Anti-Parkinson Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 58. UAE Anti-Parkinson Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 59. AbbVie Revenue Growth Rate in Anti-Parkinson Drugs Business (2016-2021)
    Figure 60. Mylan Laboratories Revenue Growth Rate in Anti-Parkinson Drugs Business (2016-2021)
    Figure 61. Valeant Pharmaceuticals Revenue Growth Rate in Anti-Parkinson Drugs Business (2016-2021)
    Figure 62. Novartis Revenue Growth Rate in Anti-Parkinson Drugs Business (2016-2021)
    Figure 63. GlaxoSmithKline Revenue Growth Rate in Anti-Parkinson Drugs Business (2016-2021)
    Figure 64. Zambon Pharmaceuticals Revenue Growth Rate in Anti-Parkinson Drugs Business (2016-2021)
    Figure 65. Pfizer, Inc. Revenue Growth Rate in Anti-Parkinson Drugs Business (2016-2021)
    Figure 66. Hoffmann-La Roche Revenue Growth Rate in Anti-Parkinson Drugs Business (2016-2021)
    Figure 67. Merck & Co. Revenue Growth Rate in Anti-Parkinson Drugs Business (2016-2021)
    Figure 68. Orion Pharma Revenue Growth Rate in Anti-Parkinson Drugs Business (2016-2021)
    Figure 69. UCB Revenue Growth Rate in Anti-Parkinson Drugs Business (2016-2021)
    Figure 70. Teva Pharmaceutical Industries Ltd. Revenue Growth Rate in Anti-Parkinson Drugs Business (2016-2021)
    Figure 71. Vertical Pharmaceuticals, LLC Revenue Growth Rate in Anti-Parkinson Drugs Business (2016-2021)
    Figure 72. ACADIA Pharmaceuticals Inc. Revenue Growth Rate in Anti-Parkinson Drugs Business (2016-2021)
    Figure 73. Bottom-up and Top-down Approaches for This Report
    Figure 74. Data Triangulation
    Figure 75. Key Executives Interviewed
SELECT A FORMAT
Added to Cart

Electronic (PDF)
$3900
This license allows only one user to access the PDF.

Electronic (PDF)
$5850
This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Electronic (PDF)
$7800
This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (10% Discount)
OUR CUSTOMER
Strategic Venue Partners

RELATED REPORTS

Global and China Polyvinylidene Difluoride Membrane Market Insights Forecast to 2027
Global and China Polyvinylidene Difluoride Membrane Market Insights, Forecast to 2027

120 Pages
Type: Report
Code: QYRE-Auto-0J3512
Thu Sep 23 00:00:00 UTC 2021

Add to Cart

Global and Japan Solid Tumor Drug Market Insights Forecast to 2027
Global and Japan Solid Tumor Drug Market Insights, Forecast to 2027

120 Pages
Type: Report
Code: QYRE-Auto-19N6828
Thu Sep 23 00:00:00 UTC 2021

Add to Cart

Global and United States Industrial Grade Hydrogel Market Insights Forecast to 2027
Global and United States Industrial Grade Hydrogel Market Insights, Forecast to 2027

120 Pages
Type: Report
Code: QYRE-Auto-13B4426
Thu Sep 23 00:00:00 UTC 2021

Add to Cart

Global and United States Phenylethyl Market Insights Forecast to 2027
Global and United States Phenylethyl Market Insights, Forecast to 2027

120 Pages
Type: Report
Code: QYRE-Auto-27F4141
Thu Sep 23 00:00:00 UTC 2021

Add to Cart